Estrella Immunopharma, Inc. (NASDAQ:ESLA – Get Free Report)’s share price crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $0.55 and traded as high as $0.7699. Estrella Immunopharma shares last traded at $0.7472, with a volume of 3,907,990 shares changing hands.
Analyst Ratings Changes
Separately, Weiss Ratings raised Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, October 28th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.00.
Check Out Our Latest Stock Analysis on Estrella Immunopharma
Estrella Immunopharma Stock Performance
Estrella Immunopharma (NASDAQ:ESLA – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.04. As a group, research analysts anticipate that Estrella Immunopharma, Inc. will post -0.25 earnings per share for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new position in Estrella Immunopharma stock. BlackRock Inc. purchased a new position in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 52,033 shares of the company’s stock, valued at approximately $54,000. BlackRock Inc. owned approximately 0.12% of Estrella Immunopharma at the end of the most recent quarter. Institutional investors own 0.35% of the company’s stock.
About Estrella Immunopharma
Estrella Immunopharma, Inc. (NASDAQ: ESLA) is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and other serious diseases. The company’s work centers on genetically engineered T-cell therapies designed to recognize and destroy target cells. Estrella’s lead program is EB103, a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy being developed for the treatment of certain B-cell malignancies. The company has described EB103 as being based on its ARTEMIS platform, which is intended to support targeted immune-cell activity while addressing some limitations associated with conventional CAR-T therapies.
See Also
- Five stocks we like better than Estrella Immunopharma
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Estrella Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Estrella Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
